tiprankstipranks
NeuroMetrix to exhibit Quell Fibromyalgia, new clinical data
The Fly

NeuroMetrix to exhibit Quell Fibromyalgia, new clinical data

NeuroMetrix will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 – 26 in Ft. Lauderdale, FL. In addition, two scientific posters reporting new data on the use of Quell in patients with fibromyalgia will be presented. Fibromyalgia is a chronic condition characterized by generalized pain, fatigue, poor sleep, memory and concentration impairments, mood disorders and other disabling symptoms. The prevalence of fibromyalgia is estimated to be 2 to 6 percent of the U.S. adult population Quell Fibromyalgia utilizes proprietary wearable neuromodulation technology and is the only FDA authorized medical device to help reduce the symptoms of fibromyalgia. Conference attendees are encouraged to visit the Company’s booth #32 for a demonstration and to review prescribing details. The two scientific posters listed below will be presented live on Friday, March 24 and will be available for review throughout the conference. Wearable Lower-Extremity Transcutaneous Electrical Nerve Stimulation May Improve Self-Reported Balance Impairment in Subjects with Fibromyalgia: An Exploratory Post-Hoc Analysis Balance impairment and falls are common in individuals with fibromyalgia. Data from a recently completed double-blind, randomized, sham-controlled trial of Quell in 119 subjects with fibromyalgia was analyzed. Self-reported balance impairment was assessed on an 11-point numerical rating scale. The median balance at baseline was 5. Balance impairment decreased following 3-months of active but not sham treatment. The group difference was significant. Quell may improve self-reported balance impairment in patients with fibromyalgia. Fibromyalgia Patients with Self-Reported Weather Insensitivity Exhibit an Enhanced Treatment Response to Wearable Lower-Extremity Transcutaneous Electrical Nerve Stimulation Most individuals with fibromyalgia report that weather changes exacerbate their symptoms. However, little is known about the minority that is insensitive to the effects of weather. An analysis of real-world data from 766 individuals with fibromyalgia was conducted. Participants without weather sensitivity reported greater reductions in pain-intensity, pain-interference with sleep and pain-interference with activity compared to those with weather sensitivity. If the treatment benefits of weather insensitivity can be determined, it may be possible to optimize outcomes in the overall population of fibromyalgia patients.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on NURO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles